Marex ($MRX) Omitted Forecasts and Misled Investors at IPO Case

S.D. New York

Court

1:25-cv-08393

Case number

05/16/2024

Class period Start

08/05/2025

Class period End

12/08/2025

Lead Plaintiff motion deadline

$MRX investors filed a claim against Marex Group for making false and misleading statements in connection with its IPO, including misrepresenting financial stability, downplaying trading revenue declines, and failing to disclose operational headwinds already affecting performance.
After reporting poor Q2 results just weeks after going public, $MRX fell 36.4% from June 27, 2025, to August 6.
$MRX investors can join this case to be notified about potential recovery.

Case Details:

Between June 27, 2025, and August 6, 2025, Marex completed its U.S. IPO and began publicly trading under the ticker $MRX, offering 15.4 million shares at $19.50. In its IPO registration documents, Marex highlighted strong momentum in 2024, pointing to a record performance driven by robust commodities trading, expansion into clearing and derivatives, and a diversified revenue mix.

However, the offering documents omitted key facts about Marex’s financial condition and performance trends in Q2 2025. 

Marex allegedly failed to disclose that net revenue and EBITDA were trending below internal forecasts—information known to executives before the IPO closed.

On August 6, 2025, just six weeks after the IPO, Marex released its Q2 2025 earnings, revealing:
Net revenue of $335.3M, down 8.2% from Q2 2024.
Adjusted EBITDA of $41.3M, a 47% drop YoY.
Earnings and margins significantly below consensus expectations.
The company also offered a weaker outlook for the second half of the year, citing low volatility and softer trading conditions.

Following this report, $MRX fell 36.4%, from June 27 (IPO day close) to August 6, wiping out hundreds of millions in investor capital.

Based on these events, $MRX investors filed a claim against Marex, alleging the company:
It omitted material facts in its IPO registration statement.
It misrepresented the company’s financial trajectory and growth stability.
It concealed internal forecasts that contradicted the bullish tone of its IPO.
Investors argue Marex misled the market by presenting a strong growth narrative while knowing financial performance was already deteriorating, resulting in sharp losses post-IPO.

Case Type

US Securities Class Action

Case Status

Lead Plaintiff Appointment

Alleged Offence

Financial Misrepresentation,

Fraud

Suspected Party

Management

Security Type

Stocks

Trade Direction

Long

Shock Event Date

08/05/2025

Filing date

10/09/2025

Lead Plaintiff Deadline

12/08/2025

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.